Zacks Investment Research Downgrades Arcturus Therapeutics (ARCT) to Hold

Share on StockTwits

Arcturus Therapeutics (NASDAQ:ARCT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

According to Zacks, “Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA. “

Other equities research analysts have also recently issued reports about the company. ValuEngine cut Arcturus Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, October 8th. WBB Securities upgraded Arcturus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 20th. Finally, Brookline Capital Management restated a “buy” rating on shares of Arcturus Therapeutics in a research report on Thursday, September 27th. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $8.63.

Shares of NASDAQ ARCT traded down $0.06 during midday trading on Tuesday, reaching $5.35. 400 shares of the company were exchanged, compared to its average volume of 7,280. Arcturus Therapeutics has a 1 year low of $4.11 and a 1 year high of $10.43. The firm has a market cap of $55.06 million, a P/E ratio of -1.52 and a beta of 1.93.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.04. The firm had revenue of $3.42 million for the quarter, compared to analyst estimates of $3.75 million. On average, equities analysts forecast that Arcturus Therapeutics will post -1.9 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. ARK Investment Management LLC boosted its position in Arcturus Therapeutics by 45.0% in the 3rd quarter. ARK Investment Management LLC now owns 773,772 shares of the biotechnology company’s stock valued at $6,840,000 after buying an additional 239,999 shares during the last quarter. Worth Venture Partners LLC acquired a new stake in Arcturus Therapeutics in the 3rd quarter worth $290,000. BlackRock Inc. acquired a new stake in Arcturus Therapeutics in the 2nd quarter worth $169,000. Finally, JPMorgan Chase & Co. grew its position in Arcturus Therapeutics by 91.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,744 shares of the biotechnology company’s stock worth $148,000 after purchasing an additional 8,008 shares during the last quarter. Institutional investors own 10.09% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.

Read More: Risk Tolerance

Get a free copy of the Zacks research report on Arcturus Therapeutics (ARCT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply